What do we know about the a/b for prostate cancer?

Diagnostic and therapeutic challenges for dermatologists: What shall we do when we don’t know what to do?

What shall we do when we have done everything we could for the diagnosis and treatment of a patient, but were not successful? What shall we do when there is no definite treatment for a patient? What shall we do when we have no diagnosis or treatment for a patient? Some useful suggestions are presented here to get rid of these situations.

Do We Know What We Do not Know? A Response to Celine Bonnet

What is the most appropriate test in detecting prostate cancer in patients with intermediate prostate specific antigen levels?

  Abstract   Background: Regarding the variety of tests present for detecting and also screening   prostate cancer and also bearing in mind the advantages and disadvantages of   these tests we decided to re-evaluate these tests (total prostate specific antigen and all   of its modifications) in detecting prostate cancer in men with intermediate serum   PSAlevels.   Methods: Following a cross se...

Molecular approaches to diagnosis of invasive aspergillosis what we know and what we do not know.

Invasive aspergillosis (IA) are a major complication in immunocompromized patients where can be serious and rapidly fatal. Early diagnosis and early appropriate antifungal treatment is important in reducing mortality and morbidity. But despite many efforts to develop detection methods, the diagnosis of IA still remains challenging and current conventional methods are limited for adequate diagno...

Superior Capsule Reconstruction: What Do We Know?

The management of irreparable rotator cuff tears remains challenging. Since its introduction by Mihata in 2012, superiorcapsule reconstruction (SCR) has grown in popularity at an astonishingly rapid rate. The aim of this article is to providea comprehensive review of the available literature, in order to highlight what has so far been published on SCR,covering all aspects including biomechanica...

PSA Screening in Prostate Cancer

Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...